RVMD · Healthcare
Revolution Medicines Inc
35/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
46
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$43.7B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About REVOLUTION MEDICINES INC
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early…
Who's behind the signal
Every informed buyer we can see on RVMD, across all three feeds.
Hedge funds · 8
Duquesne Family Office (Druckenmiller)
New position
Gotham Asset Mgmt (Greenblatt)
Increased +11%
D.E. Shaw & Co
Decreased −37%
Tudor Investment (Paul Tudor Jones)
Decreased −5%
Citadel Advisors
Decreased −69%
Millennium Management (Englander)
Decreased −53%
+2 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
REVOLUTION MEDICINES INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
1
Increasing
6
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.6×
% of portfolio
1.1%
Position change
NEW
1.1% of Duquesne Family Office's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+11%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−37%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.2×
% of portfolio
0.1%
Position change
−5%
0.1% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−69%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−53%
0.0% of Millennium Management's portfolio
Trust weight: 1.4×
% of portfolio
0.0%
Position change
−4%
0.0% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−8%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to REVOLUTION MEDICINES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell REVOLUTION MEDICINES INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订